Breaking News, Collaborations & Alliances

CellCarta, Pillar Biosciences Partner to Expand Access to Tumor Profiling

The collaboration combines Pillar’s portfolio of NGS-based kitted panels with CellCarta’s global expertise in clinical trial testing.

Author Image

By: Patrick Lavery

Content Marketing Editor

CellCarta and Pillar Biosciences are launching a global, multi-year strategic partnership to broaden access to next-generation sequencing (NGS) tumor profiling. The two companies say the fast, and streamlined services will be available to biopharma sponsors and clinical research partners alike. CellCarta is a global precision medicine lab services provider for drug development; Pillar Biosciences specializes in NGS-based oncology molecular diagnostics. Pitfalls in the Tumor Profiling Proce...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters